Kornimate/medical-research-clean huggingface dataset:
cannabidiol (cbd) for the management of cannabis withdrawal: a phase ii proof of concept study

Conditions: Cannabis Use Disorder

Summary: single subject repeated measures design of an open label administration of cannabidiol (cbd) to 5 participants withdrawing from cannabis use in an inpatient setting. 300mg of cbd will be administered once on day 1, twice on days 2-5 and once on day 6. participants will be discharged on day 7. cbd will be administered orally in capsules.


Eligibility criteria:
inclusion criteria: participants must be seeking treatment for cannabis use disorder and report having experienced cannabis withdrawal symptoms in past quit attempts (as defined by participants' experiencing 3 or more symptoms after cessation of prolonged cannabis use or continuing use to avoid withdrawal symptoms). they must meet the criteria for a dsmv current cannabis use disorder and test positive to thc on urinary dip stick test on admission. they must be aged 18-65 and speak english. exclusion criteria: the aim is to exclude individuals with concurrent conditions that jeopardise patient safety or confound study data interpretation. these include (a) presence of another substance use disorder, operationalized as (i) more than twice weekly use of an illicit drug in the last 90 days (other than cannabis), (ii) alcohol audit scores of greater than 15, or a current history of alcohol dependence, (iii) substance use treatment in the last 30 days, or (iv) current prescription drug abuse or dependence (benzodiazepines, opioids or psychostimulants); (b) evidence of unstable or severe medical conditions or cognitive or psychiatric impairment (including developmental disorder, schizophrenia or other psychotic disorders) that may prevent participation; (f) known or suspected allergy to propylene glycol, corn oil; (h) women of child bearing age not on a reliable contraceptive or men intending to start a family with one month of trial participation; (i) pregnant or lactating women; (j) not available for follow-up; (k) no access to telephone; or (l) unwillingness to provide written confirmation that they have been informed about, and will comply with, exclusion from driving when receiving medication. only persons meeting all criteria will be assessed by trial medical officers and research staff as appropriate.

Keywords: cannabidiol cbd marijuana withdrawal treatment
exercise training and inflammatory mediators in copd

Conditions: COPD

Summary: chronic obstructive pulmonary disease (copd) is widely spread all over the world. it is predicted to be the third leading cause of death by 2020\[1\]. copd is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable\[2\].

chronic obstructive pulmonary disease (copd) is widely spread all over the world. it is predicted to be the third leading cause of death by 2020. copd is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversable.not only the long-term exposition to noxious particles and gases contributes to the development of copd, but also so many others factors such as genetics and cigarette smoking. it has been shown that cigarettes are harmful and contributed to different extra pulmonary disorders. indeed, it induced a systemic inflammation that was considered as a key process in the pathogenesis of copd and triggered the activation of inflammatory cells and an abnormal increase of circulating cytokines such as crp, interleukin (il6), il8, tumor necrosis factor alpha (tnf alpha) and leptin.

Eligibility criteria:
inclusion criteria: * copd diagnosed by pulmonary function testing * clinically stable * abscence of other obstructive diseases * signed written consent exclusion criteria: * neuromuscular diseases -severe psychiatric, neurologic or musculoskeletal conditions and /or instable--- -- * cardiovascular diseases. * contre-indications to physical therapy * acute exacerbations a month before the intervention

Keywords: copd inflammation exercise training
pulsed short wave in females with knee osteoarthritis

Conditions: Chronic Diseases; Knee Osteoarthritis

Summary: study design: randomized clinical trial. objective: to evaluate the effect of psw treatment in different doses and to compare to the control and placebo group. background: several forms of conservative treatment have been the focus of many recent studies in knee osteoarthritis (oa). among these techniques, the application of pulsed short wave has been widely used, but the optimal dose and application time still have not been well established.

methods: one hundred and twenty-one females (average ± sd age, 60 ± 9 years), with a diagnosis of knee oa were distributed randomly into 4 groups: 35 patients who did not receive any treatment (control), 23 patients in the placebo group, 32 patients in the low dose psw group (14.5w, 19 minutes and 17kj), and 31 patients in the high dose psw group (14.5w, 38 minutes and 33kj). an 11-point numerical pain rating scale (nprs) and "knee osteoarthritis outcome score" (koos) were used to assess pain and function in 3 stages: initial evaluation (pre-treatment), immediately after post-treatment, and a 12-month follow up. results: the 4 groups were homogeneous prior to treatment with respect to demographics, pain, and functional scales data. we demonstrated the short-term effectiveness of the psw at low or high doses in patients with knee oa. both treatment groups showed significant improvement in pain and function when compared to the control and placebo groups (p\<0.05). there were no differences between psw doses, despite the fact that a low dose of psw seems to be more effective in the long term. conclusion: the psw is an effective method for pain relief, functionality, and quality of life improvement in females with knee osteoarthritis in the short-term. on the basis of our results, we recommend psw application in the female population with knee oa. however, conclusions regarding the 12-month follow up should be analyzed carefully due to the high dropout rate.

Eligibility criteria:
inclusion criteria: * the female subjects were included if they were over 40 with knee primary grade ii or iii oa, based on gupta et al radiographic criteria2, and joint or anterior knee pain for at least 3 months. exclusion criteria: * we excluded patients with a history of surgery or any invasive procedure of the affected knee, physical therapy for knee injuries or any medication that had changed in the last 3 months, other diseases changing function, and patients who presented any contraindication for psw application, especially metallic implants, pacemakers, lack of sensitivity, or tumor.

Keywords: knee osteoarthritis physical therapy pulsed short wave
efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg after 1 week of treatment withdrawal

Conditions: Hypertension

Summary: this study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level ras cascade inhibition. the purpose of this study was to compare the prolonged efficacy and safety of aliskiren to that of telmisartan in mild to moderate hypertensive patients in the 24 hrs ambulatory blood pressure monitoring setting after a one week treatment withdrawal.


Eligibility criteria:
inclusion criteria: * mean sitting systolic blood pressure ≥ 140 mmhg and \< 180 mmhg * 24-hr mean ambulatory systolic blood pressure ≥ 135 mmhg exclusion criteria: * severe hypertension defined as mean sitting systolic blood pressure ≥ 180 mmhg and/or mean sitting diastolic blood pressure ≥ 110 mmhg * patients with type 1 diabetes mellitus * secondary hypertension of any etiology * other protocol-defined inclusion/exclusion criteria may apply

Keywords: hypertension abpm systolic blood pressure diastolic blood pressure cardiovascular disease aliskiren telmisartan
eribulin in mtnbc patients

Conditions: Breast Cancer

Summary: to evaluate the efficacy and safety of eribulin in patients with advanced breast cancer.


Eligibility criteria:
inclusion criteria: 1. advanced breast cancer included unresectable locally advanced breast cancer, de novo stage iv breast cancer, and recurrent metastatic breast cancer. 2. eribulin treatment of advanced breast cancer for at least one cycle, between dec 2019 and aug 2020. 3. available medical history. exclusion criteria: 1. incomplete medical history.

Keywords: eribulin tnbc
analysis of health status of сomorbid adult covid-19 patients hospitalised in second wave of sars-cov-2 infection

Conditions: Covid19; Comorbidities and Coexisting Conditions; Risk Factor, Cardiovascular; Death; Diabetes; COPD; Atrial Fibrillation; DVT; CKD

Summary: comparison of covid-19 disease course in hospitalized patients infected by sars-cov-2 in first and second waves of the novel coronavirus infection

non-commercial depersonalized multi-centered registry study on analysis of chronic non-infectious diseases dynamics after sars-cov-2 in first and second waves of the novel coronavirus infection in cohort of russian adult patients. retrospective analysis of medical histories and outcomes in adults with pre-existing conditions after sars-cov-2 infection. comorbidities worsening risk factors measuring through evaluation of range of indicators such as dynamics of diabetes, ckd, copd, bronchial astma, incidence of hypertonic crises, vascular events and others.

Eligibility criteria:
inclusion criteria: suspected or confirmed covid-19 (according to results of swab-test, antibody test, computed tomography or radiography image) exclusion criteria: 1. unwillingness to participate in the study; 2. age under 18.

Keywords: covid19 comorbidities and coexisting conditions risk factor sars-cov-2 covid-19 second wave covd-19 first wave death
a double-blind placebo controlled trial of riluzole in bipolar depression

Conditions: Bipolar Disorder

Summary: the johns hopkins department of psychiatry is conducting a research study to examine the effectiveness of riluzole in treating the depressed phase of bipolar disorder. this outpatient treatment study of medication or placebo will last 9-12 weeks. the study includes medical and psychiatric evaluations as well as time-limited medication treatment at no cost, and you will be compensated for your participation.

the study will last 8 to 12 weeks and requires weekly visits. participants will come to johns hopkins for a screening visit during which they will talk with a psychiatrist, answer questions about their mood and symptoms, have their blood drawn and have a brief physical exam. if they meet criteria for the study, any antidepressant medication that they are taking will be tapered and stopped before beginning study medications. participation in the study includes free study medication, labs, and testing plus reimbursement for transportation. participants will also be paid and after the study referred back to their treating psychiatrist with treatment recommendations.

Eligibility criteria:
inclusion criteria: * ages 18-75 * diagnosed with bipolar i or ii disorder and currently depressed * tried at least one antidepressant during the current episode of depression * currently taking either lithium, depakote, or tegretol * currently in outpatient treatment with a psychiatrist exclusion criteria: * current psychotic symptoms * women who are pregnant or nursing * any serious, uncontrolled medical illness * history of liver problems * current or past blood diseases * current drug or alcohol abuse * currently receiving electroconvulsive shock therapy (ect) * judged to be at serious suicidal risk

Keywords: bipolar depression
the effect of using medial longitudinal arch supported insoles on jumping in young football players

Conditions: Pes Planus; Sports Physical Therapy

Summary: in this study, it was aimed to determine the effect of pressing styles and insoles on jumping performances.

in this clinical study, 30 healthy male football players between the ages of 16-20 will be carried out at kasımpaşa sports club academy. in the study, the effect of medial longitudinal arch height and the use of insoles on jumping using vertical jump, countermovement jump and drop jump tests will be investigated. football players; medial longitudinal arch heights will be measured by applying foot posture index-6 and navicular position test. as a result of these measurements; flat sole, normal sole and high sole will be divided into three groups. these three groups; vertical jumping, countermovement jumping and drop jumping tests will be applied with the help of portable jumping apparatus and the results will be recorded. these tests will be re-applied to all three groups with a non-personalized, prefabricated insole that supports the medial arch. according to these tests, it will be investigated whether jumping performance depends on medial arch height. it will be evaluated whether there is a change in jumps after the insoles used. the obtained data will be analyzed statistically.

Eligibility criteria:
inclusion criteria: * football players between the ages of 16-20 will be included in the study. * football players who were not injured at the time of the study were included in the study will be. * football players who allow and want to participate in the study will be included in the study. exclusion criteria: • football players who had an injury at the time of the study were included in the study will not be.

Keywords: jumping insoles footballer
effects of low-level mechanical vibration on bone density in ambulant children affected by duchenne muscular dystrophy

Conditions: Osteoporosis; Duchenne Muscular Dystrophy

Summary: duchenne muscular dystrophy (dmd) is a x-linked recessive disorder due to a mutation of the dystrophin gene (xp21). dystrophin is a sarcolemmal protein of skeletal and cardiac muscle, and its absence causes progressive muscle degeneration and substitution with fat and connective tissue. the progressive muscle degeneration leads to loss of autonomous walking before the age of 15 years and death for cardiac and/or respiratory failure. there are no specific treatment for dmd, and the standard of care is now based on long-term corticosteroid (cs) use. the studies on bone mass in dmd are very few, but they agree in reporting the presence of a reduced bone mass and an increased rate of fractures probably due to long-term steroid therapy and disuse-osteopenia. the aim of this study, involving 20 ambulant dmd boys (age 7-10 years) has been the evaluation of the effects of low-level mechanical vibrations on bone in a group of ambulant dmd children for 1 year, with rda-adjusted dietary calcium intake and 25oh vitamin d supplementation.

all children were instructed to have a daily intake of calcium equal to the 100% of the rda and were supplemented with calcifediol (0.7 mcg/kg/die). the 20 boys were randomly assigned to two groups: group 1 (mechanical intervention group) = a mechanical device (a small platform designed to induce vertical, sinusoidal acceleration) was installed in the home of each boy of group 1. group 2 (placebo control group) = a placebo device was installed in the home of each boy of group 2 all boys were instructed to stand on the platform for 10 minutes each day for 12 months. compliance was followed and stimulated through weekly telephone contacts with parents and children.

Eligibility criteria:
inclusion criteria: * diagnosis of dmd * ability to stand up and walk (some balance assistance allowed, but full weight-bearing necessary) * all the children must already be on glucocorticoid therapy for at least 6 months before the start of the study. exclusion criteria: * presence of other diseases interfering with bone density and bone turnover * the inability to regularly use the vibratory platform.

Keywords: duchenne muscular dystrophy children low bone mass osteoporosis low-level mechanical vibration bone turnover markers
the effect of vibration applied on forearm extensor muscles patients with stroke

Conditions: Stroke Patients

Summary: this study was planned to determine the effect of vibration applied to forearm extensor muscles on hand functions and muscle activation in stroke patients.

patients will be included in our study, who will be hospitalized in kirikkale university faculty of medicine physical therapy hospital and will receive stroke rehabilitation. the number of patients will be determined to be approximately 24 according to the power analysis. patients meeting the inclusion criteria and excluding the exclusion criteria will be randomized according to the order of arrival and divided into 2 groups as the training group and the control group. patients will be randomized using block randomization. routine conventional physical therapy will be applied to the patients in the vibration group in 4 weeks and 45 minutes sessions. in addition, 30 hz, 3 days a week, immediately after the sessions, to the forearm extensor group muscles with ''conformité européene'' certified vibration device. frequency vibration will be applied. a vibration session will be as follows; 6 sets of vibrations will be applied, including 1 set of 1 minute vibration and 2 minutes of rest. routine conventional physical therapy will be applied to the control group in 4 weeks and 45 minute sessions.

Eligibility criteria:
inclusion criteria: * diagnosed with stroke * cognitive and without communication problems * patients with active movement in the upper extremities exclusion criteria: * people who have undergone botulinum toxin application to the upper extremity * significant cognitive impairment that will interfere with functional evaluation * deformity and / or contracture in the upper extremity due to fractures, inflammatory arthropathy, etc. * infection, skin lesion or hematoma at the application site

Keywords: stroke rehabilitation vibration hand functions forearm extensor muscle
the choice of treatment methods and efficacy of labc

Conditions: Locally Advanced Breast Cancer

Summary: the goal of this clinical trial is to compare the therapeutic effects of chemotherapy followed by surgery and surgery followed by chemotherapy in patients with locally advanced breast cancer（labc). patients with labc will be randomly divided into two groups, each receiving chemotherapy followed by surgery or surgery followed by chemotherapy. the main comparison was between the disease-free survival (dfs) of two groups of patients, with the secondary study endpoint being overall survival (os); five year survival; local recurrence or distant metastasis rate.

local advanced breast cancer was enrolled in the department of breast surgery of peking union medical college hospital and beijing cooperation hospital according to the criteria for patient inclusion. it is estimated that 50 patients will be enrolled. randomly divide patients into two groups. the plan for group a (experimental group, 25 cases) is "surgery+systematic treatment"; the plan for group b (control group, 25 cases) is "neoadjuvant therapy+surgery+systematic treatment". based on the previously obtained patient personal information, treatment related information, tumor tissue/blood sample test results, statistical analysis was conducted to explore the impact of different treatment strategies for locally advanced breast cancer on the survival and prognosis of patients.

Eligibility criteria:
inclusion criteria: 1. 18-70 year old female 2. patients with locally advanced breast cancer (stage iiib - iiic) first diagnosed; 3. clinical diagnosis of breast cancer, or puncture pathology suggests breast cancer; 4. after evaluation by experienced clinical physicians, the patient's tumor has the possibility of surgical resection. specific evaluation indicators include ultrasound assessment of the tumor not surrounding the axillary vein; 5. accept treatment plans including surgery, radiotherapy, and chemotherapy; 6. volunteer to participate in clinical research and sign an informed consent form; 7. willing to undergo follow-up and complete quality of life (eq-5d series scale and fact-b scale) and postoperative psychological status (anxiety/depression self rating scale) assessments; exclusion criteria: 1. patients under 18 years old or over 70 years old; 2. those who have received breast cancer related surgery, radiotherapy or chemotherapy; 3. those who are not expected to receive surgery, radiotherapy or chemotherapy related to breast cancer 4. history of other malignant tumors; 5. pregnant or lactating women; 6. accompanying active infection and fever; 7. other serious diseases that may significantly affect clinical trial compliance, such as severe cardiopulmonary dysfunction, liver and kidney dysfunction, poorly controlled diabetes and mental illness.

Keywords: locally advanced breast cancer prognosis
determinants of corticosteroid insensitivity in smokers with asthma

Conditions: Asthma; Smoking; Steroid Resistance; Corticosteroid Insensitivity

Summary: smokers with asthma display a relative insensitivity to inhaled and oral corticosteroids. the causes of this phenomenon are currently unknown. the investigators will perform a number of blood \& breathing tests to try to discover the cause/s behind this phenomenon with the aim of producing leads for further investigation and possible new treatments for smokers with asthma.

smokers with asthma display a relative insensitivity to inhaled and oral corticosteroids. the causes of this phenomenon are currently unknown. however research into steroid resistance in severe asthma and the smoking related condition chronic obstructive pulmonary disease (copd) points to a number of possible causes. we will characterise a group of smokers with asthma and perform a number of investigations and compare the results to ex-smokers and never smokers with asthma with the aim of establishing which previously published steroid resistance phenomena are related to the steroid resistance displayed by smokers with asthma. results produced from this trial will provide hypothesis generating information leading to future pharmaceutical trials.

Eligibility criteria:
inclusion criteria: * asthma (defined by either reversibility to bronchodilator or methacholine testing) * asthma duration of 6 months or greater * stable asthma * age 18-60 * treatment with inhaled corticosteroids * smoking history consistent with group * smokers with asthma: \> or = 5 pack years and currently smoking more than 5 cigarettes per day * ex-smokers: smoking ceased \> or = two years prior to recruitment, minimum 5 pack year history * non-smokers: no smoking history exclusion criteria: * presence of medical condition likely to be exacerbated by treatment with oral corticosteroids * treatment with \> 2000 mcg beclomethasone (or equivalent) per day * subject requires oral corticosteroids to maintain asthma control * subject requires oral theophylline to maintain asthma control * recent treatment with oral corticosteroids * pregnancy or subject planning to become pregnant

Keywords: asthma smoking steroid resistance corticosteroid insensitivity